Folate-targeted immunotherapies: Passive and active strategies for cancer

Batoul Farran; Eluri Pavitra; Prameswari Kasa; Sujatha Peela; Ganji Seeta Rama Raju; Ganji Purnachandra Nagaraju

doi:10.1016/j.cytogfr.2019.02.001

Folate-targeted immunotherapies: Passive and active strategies for cancer

Batoul Farran
, Eluri Pavitra
, Prameswari Kasa
, Sujatha Peela
, Ganji Seeta Rama Raju
, Ganji Purnachandra Nagaraju

Emory University
Inha University
Dr. LV Prasad Diagnostics and Research Laboratory
Dr. B.R. Ambedkar University, Srikakulam

Research output: Contribution to journal › Review article › peer-review

49 Scopus citations

Abstract

The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.

Original language	English
Pages (from-to)	45-52
Number of pages	8
Journal	Cytokine and Growth Factor Reviews
Volume	45
DOIs	https://doi.org/10.1016/j.cytogfr.2019.02.001
State	Published - Feb 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Folate receptor
Immune therapy
Solid cancers
Targeted therapy
Vaccines

Access to Document

10.1016/j.cytogfr.2019.02.001

Cite this

@article{c54de4883eff41f4a9c07471e1551366,

title = "Folate-targeted immunotherapies: Passive and active strategies for cancer",

abstract = "The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.",

keywords = "Folate receptor, Immune therapy, Solid cancers, Targeted therapy, Vaccines",

author = "Batoul Farran and Eluri Pavitra and Prameswari Kasa and Sujatha Peela and \{Rama Raju\}, \{Ganji Seeta\} and Nagaraju, \{Ganji Purnachandra\}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = feb,

doi = "10.1016/j.cytogfr.2019.02.001",

language = "English",

volume = "45",

pages = "45--52",

journal = "Cytokine and Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Folate-targeted immunotherapies

T2 - Passive and active strategies for cancer

AU - Farran, Batoul

AU - Pavitra, Eluri

AU - Kasa, Prameswari

AU - Peela, Sujatha

AU - Rama Raju, Ganji Seeta

AU - Nagaraju, Ganji Purnachandra

PY - 2019/2

Y1 - 2019/2

N2 - The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.

AB - The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.

KW - Folate receptor

KW - Immune therapy

KW - Solid cancers

KW - Targeted therapy

KW - Vaccines

UR - https://www.scopus.com/pages/publications/85061339191

U2 - 10.1016/j.cytogfr.2019.02.001

DO - 10.1016/j.cytogfr.2019.02.001

M3 - Review article

C2 - 30770191

AN - SCOPUS:85061339191

SN - 1359-6101

VL - 45

SP - 45

EP - 52

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

ER -

Folate-targeted immunotherapies: Passive and active strategies for cancer

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this